COMMUNIQUÉS West-GlobeNewswire

Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26/01/2026
ELPIS II top-line trial results are anticipated in the third quarter of 2026 Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS II results are [...]
DoseSpot's pVerify Achieves Multiple 2025 Recognitions from Gartner Digital Markets' Capterra, Software Advice and GetApp
26/01/2026
BOSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- DoseSpot , which delivers best-in-class e-prescribing, insurance verification and revenue cycle management solutions for healthcare providers, announced today that its pVerify [...]
Quantum Brainwave Protocol Product Information Updated as Consumer Interest in Digital Audio Relaxation Programs Grows in 2026
26/01/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching digital audio relaxation programs New York, NY, Jan. 26, 2026 (GLOBE [...]
Purely Me Skin Tag Remover Product Information Updated as Consumer Interest in At-Home Skin Tag Solutions Grows in 2026
26/01/2026
An informational overview examining category context, publicly available product disclosures, and what consumers often consider when researching non-prescription skin tag products New York, NY, Jan. 26, 2026 (GLOBE [...]
Health-ISAC 2026 Report Details Rising Cyber Threats Across Health Sector
26/01/2026
Report highlights rising ransomware attacks, third-party vulnerabilities, and evolving social engineering tactics shaping health sector security ORLANDO, Fla., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Health-ISAC today [...]
BlueOcean Global Announces FDA 510(k) Clearance of the Excelsior™ External Fixation System
26/01/2026
MIAMI, Jan. 26, 2026 (GLOBE NEWSWIRE) -- BlueOcean Global Corp., a medical device company focused on limb preservation and complex reconstruction, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance [...]
New Clinical Data Demonstrate that VIVUS’ QSYMIA® in Combination with Digitally Enhanced Lifestyle Interventions (DELI) Leads to Significantly Greater Reductions in Weight and Cardiovascular Risk Compared with DELI Alone in Adults with Obesity
26/01/2026
— Participants in the combined treatment group lost significantly more weight at 3, 6, and 12 months and were more likely to lose 5%, 10%, or >15% of their body weight at 12 months compared with DELI alone CAMPBELL, [...]
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
26/01/2026
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari’s proprietary PH1 spliceosome payload and a novel antibody construct to address one of [...]
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures
26/01/2026
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI [...]
Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
26/01/2026
Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID ® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated in [...]
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
26/01/2026
SciSparc intends to target the global multi- billion dollar GERD device market TEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a company engaged in clinical- [...]
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program
26/01/2026
Topline data expected in 1Q 2028 Phase 2 bipolar depression trial initiation follows positive Phase 2 results in acute schizophrenia NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB [...]
Arcutis Biotherapeutics, Inc. Announces Termination of Promotion Agreement with Kowa
26/01/2026
WESTLAKE VILLAGE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Leios Therapeutics and BNC Korea Announce Strategic Collaboration to Accelerate Development of 10XB-101 in South Korea
26/01/2026
10XB-101 Being Developed for Focal Fat Reduction and Body Contouring LA JOLLA, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Leios Therapeutics, a clinical-stage biotechnology company focused on innovative aesthetic [...]
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
26/01/2026
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo., Jan. 26, 2026 (GLOBE NEWSWIRE [...]
Primmune Therapeutics Announces Additional Close of Series B Financing
26/01/2026
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Today, Primmune Therapeutics , a biotech company harnessing the power of the innate immune system, announced an additional close of its Series B financing round for a total [...]
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
26/01/2026
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insured patients Launch [...]
Genyro Signs Exclusive License for “Sidewinder,” a Breakthrough DNA Construction Technology Featured in Nature
26/01/2026
A major technological advance in DNA writing enables researchers to construct and create in the language of biology SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Genyro Inc., a biotechnology company advancing next- [...]
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture
26/01/2026
UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today provided an operational update on [...]

Pages